Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer - Summary - MDSpire

Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer

  • By

  • Su Zhang

  • Hanghao Zhang

  • Xingwang Dong

  • Zhen Qi

  • Yingjun Ma

  • Hong Chang

  • Ye Li

  • Wei Zhang

  • June 8, 2026

  • 0 min

Share

Objective:

To report cases of early tumor regression after limited-course immunotherapy in patients with bulky muscle-invasive bladder cancer (MIBC) and assess bladder preservation outcomes.

Key Findings:
  • Both patients exhibited significant tumor regression after limited-course immunotherapy.
  • Both patients declined radical cystectomy despite recommendations.
Interpretation:

Limitations:
  • The findings are based on only two cases and do not support routine omission of radical cystectomy.
  • Interval cystoscopic surveillance was incomplete.
Conclusion:

These cases highlight early tumor regression with immunotherapy in bulky MIBC.

Original Source(s)

Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer

  • by Su Zhang, Hanghao Zhang, Xingwang Dong, Zhen Qi, Yingjun Ma, Hong Chang, Ye Li, Wei Zhang

  • June 8, 2026

Related Content

Targeted therapy in thyroid cancer: molecular alterations and clinical management

Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential

Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma